Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. (en)
|
http://linked.open...generalReferences
| - # Hold KM, de Boer D, Bos KL, van Ooijen RD, Zuidema J, Maes RA: Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. J Chromatogr Sci. 1996 Jan;34(1):13-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8586675 # Himori N, Ishimori T, Izumi A, Hiramatsu Y: Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15525 (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- withdrawn (en)
|
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the treatment of hypertension, angina, and arrhythmia (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Alprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. (en)
|
http://linked.open...y/drugbank/patent
| |
http://linked.open.../drugbank/synonym
| - Alprenolol (en)
- 1-(2-Allylphenoxy)-3-isopropylamino-2-propanol (en)
- 1-(O-Allylphenoxy)-3-(isopropylamino)-2-propanol (en)
- Alfeprol (en)
- Alprenololum (en)
- Alprénolol (en)
- Aprenololo (en)
- (RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol (en)
|
http://linked.open...drugbank/toxicity
| - LD<sub>50</sub>=597.0 mg/kg (Orally in rats) (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| |
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...aco2-Permeability
| |
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |